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Abstract 
With estimated worldwide cost over $1 trillion just for dementia, diseases of the central nervous 
system pose a major problem to health and healthcare systems, with significant socio-economic 
implications for sufferers and society at large. In the last two decades, numerous strategies and 
technologies have been developed and adapted to achieve drug penetration into the brain, 
evolving alongside our understanding of the physiological barriers between the brain and 
surrounding tissues. The blood brain barrier (BBB) has been known as the major barrier for 
drug delivery to the brain. Both invasive and minimally-invasive approaches have been 
investigated extensively, with the minimally-invasive approaches to drug delivery being more 
suitable. Peptide based brain targeting has been explored extensively in the last two decades. 
In this review paper, we focused on self-assembled peptides, shuttle peptides and nanoparticles 
drug delivery systems decorated/conjugated with peptides for brain penetration. 
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Abbreviations 
α-Syn α-synuclein 
ABCB1 ATP-binding cassette sub-family B member 1 (ABCB1) 
AC Astrocyte 
AChR Acetylcholine receptor 
AD Alzheimer’s disease 
AF6 LL1-fused gene from chromosome 6 protein 
AFM Atomic force microscopy 
AMT Adsorptive-mediated transport 
ANG Angiopep 
ApoB Apolipoprotein B 
ApoE Apolipoprotein E 
AuNP Gold nanoparticle 
ASNP Alginate-stearic acid nanoparticles 
B6 CGHKAKGPRK peptide 
BBB Blood-brain barrier 
BCSFB Blood-cerebrospinal fluid barrier 
BSA Bovine serum albumin 
CNT Carbon nanotubes 
CMC Critical micelle concentration 
CNS Central nervous system 
CSF Cerebrospinal fluid 
DLS Dynamic light scattering 
EAE Experimental autoimmune encephalomyelitis 
ECs Endothelial cells 
FBS foetal bovine serum 
FITC Fluorescein isothiocyanate 
g7 7-amino acid glycoprotein, GFtGPLS (O-β-d-Glucoseglucose)CONH2 
GE11 CYHWYGYTPQNVI peptide 
GSH Glutathione 
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HD Huntington’s disease 
HIFU High-intensity focused ultrasound 
HuHtt Human huntingtin exon 1 
IFN-α Interferon-α 
IFN- Interferon gamma 
i.v.  Intravenous 
Lamp2b Lysosome-associated membrane protein 2b 
LDLR Low-density lipoprotein receptor 
LRP-1 lipoprotein receptor-related protein 1 
MCAO Middle cerebral artery occlusion 
miniAp-4 H-DapKAPETALD-NH2 peptide 
MMP Matrix metalloproteinase 
MND Motor neurone disease 
MOR Opioid receptor mu 
MS Multiple sclerosis 
MSC Mesenchymal stem/stromal cell 
MWCNT Multi wall carbon nanotubes 
nAChR Nicotinic acetylcholine receptor 
ND Neurodegenerative Disease 
NP Nanoparticle 
NIR Near infrared 
NVUs Neurovascular Units 
NW Nanowire 
PAH Poly allylamine hydrochloride 
PD Parkinson’s Disease 
PEG Polyethylene glycol 
PepH3 AGILKRW peptide 
PLA Poly(lactic acid) 
PMNP Polymeric nanoparticles 
pSiNPs Porous silica nanoparticles 
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RES Reticuloendothelial system 
ROS Reactive oxygen species 
RVG Rabies virus glycoprotein 
RVG-29 YTIWMPENPRPGTPCDIFTNSRGKRASNG 
SWCNT Single wall carbon nanotubes 
SE Status epilepticus 
SEM Scanning electron microscopy 
siRNA Small interfering RNA 
SNALP Stable nucleic acid lipid particle 
SPION Superparamagnetic iron oxide nanoparticle 
t-MCAO transient middle cerebral artery occlusion 
TAT Trans-activating transcriptional activator 
TEM Transmission electron microscopy 
Tf Transferrin 
TfR Transferrin receptor 
TJ Tight junction 
TNF-α Tumor necrosis factor-α 
WHO World Health Organisation 
ZO Zonula occludens (a.k.a. tight junction protein) 
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1. Introduction 
The central nervous system (CNS) comprises the brain and the spinal cord. Any injury or 
damage to the CNS affects its normal functioning and may lead to permanent disability in many 
cases, due to a largely limited ability for neural tissue regeneration in humans [1, 2]. The broad 
term “Neurodegenerative Diseases” (NDs) covers a range of pathologies, principally affecting 
neurons in the brain and causing significant neuronal dysfunction, neuronal death and neuronal 
loss. NDs once established are irreversible and sapping conditions resulting in progressive 
degeneration of neuronal cells [3]. The signs and symptoms are diverse in range, depending on 
the affected part of the brain. The cause of an ND is often unknown but can involve a complex 
convergence of multiple molecular mechanisms; and disease progression is usually 
unpredictable. NDs include a number of conditions: Alzheimer’s disease (AD) and other forms 
of primary dementias, Multiple Sclerosis (MS) and other forms of chronic inflammatory 
neurological disease, Parkinson’s disease (PD), Motor Neurone Disease (MND), Huntington’s 
disease (HD) and ataxias [4]. The World Health Organisation (WHO) reported that NDs affect 
around 0.1 billion individuals (24 million individuals suffer from AD and other dementias)[5] 
all over the world, and the incidence is on the rise as average life expectancy is increasing. 
Around 850,000 people in the UK are affected by dementia, costing the healthcare system over 
£26 billion a year [6]. In the US nearly 100 million people are affected by NDs costing around 
$724 billion in 2014 [7]. It is estimated that the cost of AD would be over 1 trillion dollars 
worldwide [8]; and the estimated number of people with dementia will reach 131.5 million by 
2050 [9] in the absence of effective therapies. Just in Europe, the annual cost of neurological 
disease reaches 800 billion Euros per year, with a majority attributed to direct costs [10].  
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The brain is one of the most vital and sensitive organs in the body, which, to perform its 
functions in an appropriate way, needs nutrients and gases [11]. Due to its pivotal role and 
functions, it is protected in a number of ways, including by the skull, the outer skin, three layers 
of meninges and the blood-brain barrier (BBB) [12]. The BBB is a layer of endothelial cells 
(ECs) associated with pericytes (PCs) and astrocytes (ACs) and acts as a separator of the blood 
from parenchymal cells, thus preventing penetration of drugs into the CNS. It therefore protects 
the brain from overexposure to substances such as potassium, glycine and glutamate, which, in 
high levels such as found in pathological conditions, are neurotoxic [13, 14]. 
Despite many advances in drug delivery systems that target the brain, it is still a challenging 
area. The failure of therapies administered via an intravenous (i.v.) or an oral route is often due 
to their inability to cross/penetrate the brain parenchyma. The use of peptides for drug delivery 
to the brain has been extensively explored in the last decade. Self-assembled peptides, shuttle 
peptides and peptide-decorated nanoparticles have been reported to effectively deliver drugs in 
the brain. This review covers peptide based drug delivery systems for the brain and future 
prospects. 
2. Blood-Brain Barrier 
Figure 1 is the schematic representation of healthy and diseased BBB. Numerous gateways 
have been reported to provide access the brain; the most significant are through blood stream 
or by getting access to the cerebrospinal fluid (CSF) circulation. Penetration of any molecules 
administered via the parenteral route is controlled by the BBB, the blood–cerebrospinal fluid 
barrier (BCSFB), arachnoid barrier and circumventricular organ barrier. However, drug 
molecules up taken by the brain are flushed back towards the blood through the return of the 
CSF to the blood or transporters on the BBB [15]. The BBB acts as a guard filter that prevents 
the uptake of large-molecules and more than 98% of pharmaceuticals [12, 16] and small-
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molecule drugs [17]. Small molecules that are lipid soluble, electrically neutral and weak bases 
may be able to diffuse passively across the BBB.  
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Figure 1: BBB composition and pathological conditions. (A) In normal states, the BBB comprises vascular endothelial cells connected with TJs 
and the PCs layer. A basement membrane linked with AC end-feet surrounds the endothelium. (B) Increased permeability of the BBB in pathological 
conditions results from high matrix metalloproteinase (MMP) activity and increased reactive oxygen species (ROS) and nitric oxide (NO) levels. 
Cytokines and chemokines are released and then activate microglia/macrophages, leading to basement membrane degradation, TJs disruption 
and an inflammatory response.
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Thus, the BBB, with its extensive blood capillary network, is considered the most important 
barrier that controls a molecule’s access to the brain parenchyma. Neurovascular units (NVUs) 
comprising endothelial cells, extracellular base membrane, adjoining pericytes, astrocytes, and 
microglia (although not a structural component of the BBB, are often included in the NVU as 
they influence barrier function in response to injury and disease [18] are integral parts of the 
BBB supporting system [19]. NVUs collect signals from the adjacent cells and generate 
functional responses that are crucial for appropriate CNS function [20, 21]. Both tight 
intracellular junctions (i.e. zona occludens, characteristic of the BBB) and the absence of 
fenestrations limit the permeability of drug molecules [22]. 
Various transport routes have been reported by which solutes and drug molecules can cross 
the BBB,[23, 24] as shown in Figure 2. Diffusion of substances across the BBB can be 
generally categorised into paracellular (namely the transfer of nutrients/drugs across an 
epithelium by passing through the intercellular space between the cells) and transcellular 
(namely the movements of solutes through a cell). In order to cross the BBB by passive 
diffusion, various parameters play pivotal roles. Molecular mass is an important factor and the 
ideal molecular weight reported to be suitable for passive diffusion is <400 Da [25]. A value 
of between 5.0 and 6.0 for the log of the octanol-water partition coefficient (logPo/w), a measure 
of lipophilicity, is suitable for passive diffusion [26]. 
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Figure 2. Transport routes across the BBB. Solute molecules follow from “a” to “f” pathways and the route “g” involves monocytes, macrophages 
and NPs (NPs). 
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Compounds that are lipophilic, neutral or uncharged at pH 7.4 and have less than 8 
hydrogen bonding groups are more suitable to cross the BBB [27]. In another study, reported 
by Partridge in 2012, [28] it was found that small drug molecules can cross the BBB if their 
molecular mass is less than 400 and they have the ability to form 8-10 hydrogen bonds. 
Unfortunately, it has been reported that more than 98% of drugs for the CNS are unable to 
cross the BBB adequately to attain the minimum therapeutic concentration [12]. Several 
invasive and non-invasive approaches have been anticipated to evade the BBB and enhance 
drug delivery to the CNS. 
3. Novel Shuttle peptides 
Shuttle peptides facilitate the influx of a diverse range of small molecule cargoes across 
the BBB. The concept of shuttle peptides for BBB was coined by William M Pardridge in the 
mid-1980s [29]. Small synthetic peptide shuttles (comprising natural amino acids) have been 
reported to cross the BBB. For example, the short rabies virus glycoprotein (RVG), RVG-29 
(YTIWMPENPRPGTPCDIFTNSRGKRASNG),  binds exclusively to  the nicotinic 
acetylcholine (nAChR) receptor found on neuronal cells and on the endothelial cell lining of 
the BBB, making it possible for peptide carriers to penetrate [30]. Javed et al. (2016) used C2-
9r (H2N-CDIFTNSRGKRAGGGGrrrrrrrrr, where r is D-arginine) to deliver siRNA for 
suppressing the α-synuclein (α-Syn) gene, implicated in the development of PD. 
CDIFTNSRGKRA is a shorter version of RVG, linked with four extra glycine acting as a 
spacer and positively charged arginine (R), which at the end of the C-terminus bind with 
negatively-charged siRNA. It was reported that this delivery system (peptide-based) not only 
crosses the BBB, but also stabilizes the siRNA that supresses the α-Syn protein, thus mitigating 
PD-like symptoms [31]. Although this delivery system has been derived from the rabies virus, 
it was reported to be non-toxic to neuronal cells.  
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Venom-derived, peptide-based shuttles have been reported to cross the BBB and to be able 
to deliver drugs to the desired site. Oller-Salvia et al. (2016) have demonstrated that miniAp-4 
(H-DapKAPETALD-NH2) derived from Apamin (a neurological toxin from bee venom) is able 
to cross the BBB and can deliver gold nanoparticles (NPs), showing proof of concept for drug 
delivery [32]. PepH3 (AGILKRW) has shown greater penetration upon i.v. administration in 
CD1 mice and bio-distribution was measured in mice sacrificed 5 min and 1 h after 
administration. Furthermore, its clearance and excretion is relatively fast, making it a good 
candidate for a shuttle carrier [33]. Spontaneous internalisation of nanowires (NW), linked with 
a cell penetrating peptide: the trans-activating transcriptional activator (TAT) from human 
immunodeficiency virus 1, has also been reported [34]. Two other shuttle peptides 
PWVPSWMPPRHT and GPWVPSWMPPRHT (composed of D-amino acids) have been 
found to cross the BBB and are able to transport drug molecules or diagnostic substances into 
the CNS. These peptides have been reported to be biocompatible and non-toxic (as they were 
made up of amino acids) [35]. In recent decades, a number of BBB shuttle peptides with 
improved efficiency have been reported (Table 1). Apolipoprotein (Apo) derivative peptides 
have been shown to cross the BBB (in in vitro and in vivo experiments) [36, 37]. Whilst 
numerous studies have demonstrated that Apolipoprotein B 
(ApoB) (SSVIDALQYKLEGTTRLTRKRGLKLATALSLSNKFVEGS) and Apolipoprotein 
E (ApoE) (LRKLRKRLL)2 analogues are able to cross the BBB [38, 39, 40]. Gao et al. (2012) 
reported the use PEG-(poly(ε-caprolactone)) NPs (prepared by emulsion solvent evaporation) 
for brain drug delivery, and contained docetaxel, a widely used drug in the treatment of several 
malignancies including brain tumours. They successfully conjugated a phage displayed TGN 
(Table 1) peptide and an AS1411 aptamer, which specifically targets the ligands on the BBB 
and cancer cells respectively. In vitro experiments showed excellent permeability across the 
BBB along with suitable endothelial monolayer targeting. In vivo imaging showed that 
Page 13 of 58 AUTHOR SUBMITTED MANUSCRIPT - NANOX-100084.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 Ac
ce
pte
d M
an
us
cri
pt
14 
 
unmodified NPs hardly distributed in the brain while AsNPs (AS11411 conjugated NPs) 
accumulated slightly in the brain. However, the accumulation of TGN conjugated NPs in the 
brain significantly increased and the brain distribution achieved the highest intensity at 12 h 
[41]. GRN1005 a peptide-drug conjugate (taxane paclitaxel and angiopep-2 (ANG= 
TFFYGGSRGKRNNFKTEEY)) that interacts with lipoprotein receptor-related protein 1 
(LRP1) has shown excellent permeability across the BBB. Phase I and II clinical trials 
suggested that GRN1005 was able to cross the BBB and limit tumour growth [42, 43]. 
Similarly, Li et al. (2016) used a combination of two peptides (ANG and TAT) conjugated with 
paclitaxel to deliver the drug across the BBB [44]. Zou et al. (2019) used a 16 lysine (K16) 
residue-linked low-density lipoprotein receptor-related protein (LDLR)-binding amino acid 
segment of apolipoprotein E (K16APoE) to deliver a therapeutic peptide (HAYED) into an AD 
mouse model brain leading to reduced the necrosis [45]. Numerous shuttle peptides have been 
investigated for drug delivery to the brain but there is still a need to find magical combination. 
In another study, Sonoda et al. (2018) formulated a BBB penetrant protein conjugate (JR-141), 
comprising an anti-human transferrin receptor (hTfR) antibody and human iduronate-2-
sulfatase (hIDS) to treat mucopolysaccharidosis II (MPS II, caused by accumulation of 
glycosaminoglycans) [46]. Upon i.v. administration, JR-141 was detected in the brain but hIDS 
alone failed to penetrate into the brain. In addition, ostensibly therapeutic outcomes were 
observed, with a lower accumulation of glycosaminoglycans measured in brain and peripheral 
tissues [46]. Self-assembled peptide nanoligand derived from phage display library was used 
to down regulate the BACE1 without toxicity and inflammation [47] .
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Table 1. A list of shuttle peptides that can target the BBB. 
Peptide Typical Sequence Origin Transport Mechanism Ref 
g7 GFtGPLS (O-β-d-glucose)CONH2 Enkephalin analogues/ opioid  RMT 
[48, 49, 
50, 51] 
Apamin H-CNCKAPETALCARRCQQH-NH2 Venom neurotoxin Unknown [32] 
MiniAp-4 [Dap]KAPETALD Venom neurotoxin Unknown [32] 
Regulon 
polypeptides 
PTVIHGKREVTLHL Neurotropic endogenous Protein LDLR [52] 
RAP ELKHFEAKIEKHNHYQKQLE Neurotropic endogenous Protein LDLR [52] 
Angiopep-2 TFFYGGSRGKRNNFKTEEY Neurotropic endogenous Protein LRP1 [53, 54] 
TAT (47-57) GGGGYGRKKRRQRRR HIV Protein CD4 + T lymphocytes [55] 
PhPro [Phenyl-Proline]4 Chiral library design 
Passive transport (paracellular 
and transcellular) 
[56] 
RI-OR2-TAT Ac-rGffvlkGrrrrqrrkkrGy-NH2 HIV Protein and Amyloid beta Aβ peptide binding [57] 
SynB1 RGGRLSYSRRRFSTSTGR Protegrins AMT [58] 
Pep 22 Ac-[cMPRLRGC]c-NH2 Phage display (receptor) LDLR [59] 
Leptin 30 YQQVLTSLPSQNVLQIANDLENLRDLLHLLC Leptin RMT [60] 
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TGN TGNYKALHPHNG Phage display Unknown [61, 62] 
CNG-QSH (d-CGNHPHLAKYNGT) (d-QSHYRHISPAQVC) Phage display Unknown/Aβ peptide binding [63] 
LNP KKRTLRKNDRKKRC 
the nucleolar translocation signal 
sequence of the LIM Kinase 2 
protein 
Caveolae-mediated endocytosis 
and macropinocytosis 
[64] 
ApoE (157-167) (LRKLRKRLLR)2 Apolipoprotein E LRP1 
[38, 39, 
65] 
ApoB SSVIDALQYKLEGTTRLTRKRGLKLATALSLSNKFVEGS Apolipoprotein B LRP2 [40] 
RVG-29 YTIWMPENPRPGTPCDIFTNSRGKRASNG Rabies Virus Glycoprotein nAChR [30] 
G23 HLNILSTLWKYRC Phage display GM1 and GT1b [66, 67] 
T7 HAIYPRH Phage display hTfR 
[68, 69, 
70, 71] 
THR THRPPMWSPVWP Phage display hTfR [35, 72, 
73, 74] THRre pwvpswmpprht (retro-enantio version of THR) Phage display hTfR 
THRre_2f (pwvpswmpprht)2KKGK(CF)G Branched - Phage display hTfR [75] 
DKP Phe(p-NH-Dhp)-L-N-Me[Cha]/ [2Nal] Unknown Passive diffusion [76] 
Page 16 of 58AUTHOR SUBMITTED MANUSCRIPT - NANOX-100084.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Ac
ce
pte
d M
an
us
cri
pt
17 
 
GSH-PEG GSH[PEG] Endogenous tripeptide Glutathione 
[77, 78, 
79] 
CDX D-[FKESWREARGTRIERG] Structure-guided design nAchR [80, 81] 
CRT CRTIGPSVC Phage display TfR [82] 
T7 - #2077 RLSSVDSDLSGC Phage display RMT [83] 
CAQK CAQK Phage display Proteoglycan complex [84] 
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Datta et al. (2000) used a receptor binding domain peptide derived from human 
apolipoprotein E (hApoE), LRKLRKRLLR [hApoE (141-150)] as a vehicle to cross the BBB. 
They fused hApoE (141-150) with 18A (DWLKAFYDKVAEKLKEAF) [Ac-He18a-NH2], a 
high affinity lipid-associated peptide to assess the uptake and degradation of low-density 
lipoprotein (LDL) in murine embryonic fibroblast (MEF1). In addition, four analogues were 
prepared, of which, Ac-LRRLRRRLLR-18A-NH2 [Ac-hE(R)18A-NH2] and Ac-
LRKMRKRLMR-18A-NH2 (Ac-mE18A-NH2) have an extended hydrophobic moiety, 
including the receptor binding region. Control peptides were Ac-LRLLRKLKRR-18A-NH2 
[Ac-hE(Sc)18A-NH2], which has amino acid residues of the ApoE to disrupt the hydrophobic 
face, and Ac-RRRRRRRRRR-18A-NH2 (Ac-R1018A-NH2), which has only positively 
charged arginine (R) as the receptor binding domain. Increased internalisation of LDL was 
observed by 3-, 5- and 7-fold by Ac-mE18A-NH2, Ac-hE18A-NH2, and Ac-hE(R)18A-NH2, 
respectively, whereas the control peptides had no significant biological activity as illustrated 
in Figure 3 [38]. Wang et al. (2013) used a receptor binding peptide of ApoE (residues 159-
167 [monomer: LAVYQAGAR], but the peptide had 18 amino acids, 2×monomer) fused to 
IDUA (a lysosomal enzyme, α-L-iduronidase) [IDUAe1] to deliver across the BBB by 
targeting the LRP1, for the treatment of mucopolysaccharidosis (MPS) type I [39]. Zhang et 
al. (2018) used BBB shuttle peptides to enhance the brain transduction of AAV8 after systemic 
administration. THR (THRPPMWSPVWP-NH2), a shuttle peptide that binds specifically to 
TfR1 was used to promote the internalization and transduction of AAV8 in a dose dependent 
manner [85]. 
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Figure 3. Schematic presentation of high affinity lipid peptide linked with poly-arginine and ApoE. Peptide conjugated with poly-arginine served 
as control and no permeation was observed, while conjugated ApoE showed improved internalization into cells. 
 
Page 19 of 58 AUTHOR SUBMITTED MANUSCRIPT - NANOX-100084.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Ac
ce
pte
d M
an
us
cri
pt
20 
 
4. Novel Nanotechnology for brain drug delivery 
NPs are carriers composed of natural (e.g. lipidic) or synthetic (e.g. polymeric) materials 
ranging from 1-500 nm in size. NPs are able to encapsulate, adsorb, or conjugate drugs or 
diagnostics and release the payload at a specific rate in the human body [86]. The 
physicochemical properties of NPs such as size, surface charge (zeta potential), morphology 
and composition are important factors deciding the fate of NPs, such as passage across the 
BBB, biological activity, release profile and biocompatibility [87]. A list of NPs used for brain 
drug delivery are summarised in Table 2. 
4.1. Polymeric NPs (PMNPs) 
Polymeric NPs (PMNPs) are most extensively studied for the purpose of drug delivery. 
These NPs can not only deliver small drug molecules but can also be used for the delivery of 
genes and proteins [88]. PMNPs can have good penetration through cell membranes, serum 
stability, and can be easily manufactured. Furthermore, the surface of NPs can be modified for 
various medical applications. For brain drug delivery, PMNPs are made up of proteins, amino 
acids, polysaccharides and polyesters. Different mechanisms can be adapted by the PMNPs to 
cross the BBB. They can cross the BBB either by transcytosis through endothelial cells, 
mucoadhesion, or by disturbing the TJ in the brain capillaries [89]. On the other hand, PMNPs 
can be identified upon i.v. injection by the reticuloendothelial system (RES), leading to wide 
distribution to liver, spleen and bone marrow, resulting in elimination or very short half-lives 
[90]. Tf and poly-L-arginine (cell penetrating peptide) linked with 1, 2-distearoyl-sn-glycero-
3-phosphoethanolamine-poly(ethylene glycol) (DSPE-PEG) liposomes were developed for 
brain delivery of imaging agents and DNA [91]. B6 (CGHKAKGPRK), a TfR-specific peptide, 
and GE11 (CYHWYGYTPQNVI), a peptide specific for endothelial growth factor receptor 
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(EGFR) overexpressed on cancer cells, were linked with poly(amido)amine-PEG (PAMAM-
PEG) based dendriplexes for siRNA delivery [92]. 
PLGA-NPs modified with 7-amino acid glycopeptide (g7) have been shown to deliver 
small drug molecules across the BBB in rodents. Furthermore, g7-NPs successfully crossed the 
BBB with model drug (fluorescein isothiocyanate (FITC)-albumin). Injection in wild-type and 
knockout mice clearly showed penetration into the brain [93]. Luo et al. (2017) developed high-
intensity focused ultrasound (HIFU) responsive angiopep-2-decorated poly(lactic-co-glycolic 
acid) (PLGA) hybrid NPs able to transport doxorubicin/perfluorooctyl bromide (ANP-D/P). 
Decorated-NPs showed 17-fold increased accumulation in glioblastoma and 13.4 fold higher 
than unmodified NPs. Significant amount (47%) of drug released within two minutes after 
HIFU irradiation, causing apoptosis of tumour cells [94]. Methoxypolyethylene glycol 
(MPEG) and methoxypoly(ethylene glycol)-b-polycaprolactone (PCL) NPs, conjugated with 
angiopep-2 (CTFFYGGSRGKRNNFKTKRY) peptide with encapsulation efficiency of more 
than 95% showed higher in vivo accumulation in the brain [95]. 
Di Mauro et al. (2018) developed novel biodegradable block co-polymeric NPs, 
functionalized with two different peptides AGBBB015F 
(CGGKTFFYGGSRGKRNNFKTEEY) and Regulon 
(HKKWQFNSPFVPRADEPARKGKVHIPFPLDNITCRVPMAREPTVIHGKREVTLHLHP
DH). These peptide functionalized NPs showed higher brain permeability than non-
functionalized in U-87 MG cell line [96]. K16ApoE decorated PLGA-NPs have shown better 
accumulation in the cerebral vasculature. These NPs showed higher uptake into brain and 
provided better MRI contrast for diagnostic purpose [97]. 
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4.2. Metallic NPs 
Metallic NPs for brain delivery have been under investigation due to their serum stability 
and long half-life. Ghorbani et al. (2018) reported the use of gold-iron nanocomposites 
encapsulated with curcumin-lipoic acid, a pH-sensitive delivery system for the brain. GSH is 
used as targeting ligand, leading to 2-fold increases in cellular uptake [98]. Nosrati et al. (2019) 
reported the use for glutathione (GSH) decorated iron NPs (GSHIONPs) for brain drug 
delivery. IONPs@Asp-PTX-PEG-GSH are stable, non-toxic and enhance MRI contrast for 
diagnostic purpose [99]. 
In a comparative study conducted by Wang et al. (2019) reported the peptide 
functionalized polyethylene glycol and maleic anhydride‐coated superparamagnetic iron oxide 
nanoparticles (Mal‐SPIONs) showed better diffusion to the thalamus, frontal cortex and 
temporal lobe than bovine serum albumin (BSA) conjugated NPs [100]. In another study, 
Albertini et al. (2019) used AUNPs decorated with RGD like peptides (GRGDG-NH2, 
GRGDS) for drug delivery to brain tumour. Two hours after injection, the concentrations of 
NPs were 1.5 and 5 fold higher than undecorated NPs and PEGylated NPs [101]. TAT-
conjugated gold NPs have been employed for brain drug delivery. The cellular uptake of 
AuNPs-TAT was 7.4% compared to 0.03% of AuNPs-PEG [102]. Chlorotoxin (CTX), a 
glioma specific peptide conjugated with polyethylenimine-entrapped gold nanoparticles (Au 
PENPs) showed excellent penetration into brain [103]. Ivask et al. (2018) evaluated the uptake 
of iron oxide NPs conjugated with biomimetic phosphorylcholine brushes in an in vitro BBB 
model system. They reported that after 24 h, 78% of the formulation crossed the BBB via 
adsorption mediated transport (AMT) [104]. This ability of iron oxide NPs has provided the 
opportunity of delivering therapeutic peptides to the brain by conjugating the peptide to the 
surface of iron-oxide NPs (5 nm diameter) [105]. Tf-conjugated magnetic dextran‐spermine 
NPs (DS‐NPs) have also demonstrated excellent penetration across the BBB [106]. 
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Kang et al. (2016) reported a single-step procedure to simultaneously load porous silicon 
NPs with high concentrations of siRNA and protecting them by formation of Ca2SiO4 at the 
surface of NPs (pSiNPs). These core-shell NPs had the size of 180 ± 20 nm. Then pSiNPs were 
surface functionalised with RVG peptide (cell targeting ligand) and a cell penetrating peptide 
(myr-GWTLNSAGYLLGKINLKALAALAKKIL(GGCC), a myristoylated transportan) to 
deliver the siRNA across the BBB. Addition of these peptides increased the size of pSiNPs to 
220 nm. The pSiNPs were administered intravenously to mice with brain injury, and a 
significant amounts of siRNA were accumulated at the site of injury [107]. Similarly, Lee et 
al. (2017) reported the use of rabies virus‐mimetic silica‐coated gold nanorods to treat brain 
gliomas. The nanorods were prepared by converting spherical gold NPs to gold nanorods. Then 
coating the gold nanorods with SiO2. This was to adjust the size of the nanorods to the size of 
rabies virus as much as possible. This was followed by coating the resulting Au-SiO2 nanorods 
by PEG and RVG-29. The nanorods (RVG-PEG-Au@SiO2) had the length of 117.7 ± 7.3 nm 
and width of 50.3 ± 3.1 nm. The RVG-PEG-Au@SiO2 nanorods were administered 
intravenously to orthotopic glioma-bearing mice, which in vivo fluorescence imaging indicated 
the accumulation of RVG-PEG-Au@SiO2 nanorods in the mouse brains. The mice were 
subjected to photothermal therapy using near infrared (NIR) laser. The temperature changes 
(up to 60ºC) caused by the laser therapy (localized surface plasmon resonance) of gold 
nanorods resulted in irreversible damages to or death of tumor cells. Tumor volumes in mice 
treated with RVG-PEG-AuNRs@SiO2 nanorods and applying NIR laser were considerably 
smaller than those of mice treated with PEG-AuNRs@SiO2 nanorods or control saline (124.8 
± 147.5, 1067.4 ± 295.4, and 2323.2 ± 436.3 mm3 , respectively) at 7 d after the treatment. 
Even, the tumors of two mice treated with RVG-PEG-AuNRs@SiO2 nanorods nearly vanished. 
This therapy caused slight skin damage by 808 nm laser irradiation, which was healed after 13 
days [108]. This study indicates that even the EPR of the brain tumors was not sufficient to 
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allow accumulation of PEG-AuNRs@SiO2 nanorods in the tumors and use of RVG-29 cell 
targeting peptide was necessary to achieve desired therapeutic outcomes. In addition, the size 
of RVG-PEG-AuNRs@SiO2 nanorods could be part of the successful application of these NPs.   
Numerous factors control the systemic circulation, cell penetration and BBB passage of 
NPs. Particle size is one of the important factors controlling the access of NPs across the BBB. 
Studies conducted in animal models of AD, PD and stroke have used NPs of 50-100 nm [109, 
110, 111, 112, 113, 114]. Several techniques, such as dynamic light scattering (DLS), atomic 
force microscopy (AFM), TEM and scanning electron microscopy (SEM) are used to 
characterise NPs [115]. Several factors control the particle size, such as the polymers used, 
drug loading, drug/polymer ratio and hydrophilic/lipophilic ratio. Previous studies have 
reported an increase in particle size after drug loading [116, 117]. On the other hand, Lopalco 
et al. (2015) have reported no changes in the size of NPs made up of PLGA, PLGA-d-α-
tocopheryl polyethylene glycol 1000 succinate (TGPS) and Resomer RGPd5055 pre- and post-
loading of drugs (oxcarbazepine and coumarin-6) [118]. 
4.3. Exosomes 
Exosomes are comprised of natural lipid bilayers with an abundance of adhesive proteins 
that readily interact with cellular membranes. These are small extracellular nanovesicles 
secreted by numerous cell [119, 120]. Naturally-occurring extracellular vesicles such as 
exosomes traffic endogenous small molecules, proteins and nucleic acids between cells,[121, 
122] and they have shown considerable promise for the delivery of exogenous drugs or 
biological therapeutics,[123, 124, 125, 126] including to the brain [127, 128]. Exosomes have 
several advantages over synthetic NPs in that their biocompatibility confers upon them an 
inherent non-immunogenicity and long circulation times, however surface-functionalisation 
(e.g. for targeted delivery) and synthetic analogues of ‘natural’ exosomes have also proven to 
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be successful therapeutic strategies [129, 130, 131]. Drugs delivered by means of an exosomal 
vector often show enhanced efficacy and fewer adverse effects. Enhancing and exploiting the 
innate drug-delivery capabilities of exosomes make for a highly attractive therapeutic 
approach. 
Alvarez-Erviti et al. (2011) used exosomes (obtained from self-derived dendritic cells) 
decorated to express Lysosome-associated membrane protein 2b (Lamp2b) and fused with 
neuron-specific RVG peptide to deliver siRNA into mouse brains [132]. They also compared 
the immune response of siRNA-RVG exosomes and siRNA-RVG-9R in vivo by measuring the 
interleukin (IL)-6, interferon gamma-induced protein (IP)-10, tumor necrosis factor (TNF)-α 
and interferon (IFN)-α serum levels. They found non-substantial changes in all cytokines 
compared to siRNA-RVG-9R [132]. Although, IFN-α and IP-10 increased in average for mice 
injected with siRNA-RVG exosomes compared to control mice [132]. 
Curcumin-loaded exosomes tagged with cyclo(Arg-Gly-Asp-D-Tyr-Lys) peptide 
[c(RGDyK)] were used to target the lesion region of the ischemic brain in a transient middle 
cerebral artery occlusion (tMCAO) mouse model [133]. Alvarez-Erviti et al. (2011) used RVG 
decorated exosomes to deliver siRNA to the mouse brain [132]. Long et al. (2017) used A-1 
exosomes (derived from human bone marrow mesenchymal stem/stromal cells (MSCs)) for the 
rectification of pilocarpine-induced status epilepticus (SE) [134]. Exo-JSI124 exosomes 
derived from EL-4 cells (a mouse lymphoma cell line) were used to deliver an encapsulated 
anti-inflammatory drug in experimental autoimmune encephalomyelitis (EAE) mice via an 
intranasal route, modulating inflammation [135]. Exosomes derived from dendritic cell 
cultures treated with interferon-γ were found to increase myelination in rats upon intranasal 
administration, possibly by delivery of miR-219 [136]. Exosomes loaded with 
superparamagnetic iron oxide NPs (SPIONs) and curcumin and conjugated with neuroleptin-
1-targeted peptide (RGERPRR) crossed the BBB and were used for imaging and treatment of 
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glioma [137]. Iraci et al. (2017) revealed the unexpected ability of stem cell exosomes to 
harbour and deliver functional enzymes (e.g. Asparaginase-like 1) extracellularly, thus 
behaving as fully independent small metabolic units with exciting therapeutic implications 
[138]. 
Cooper et al. (2014) described the use of exosomes derived from murine bone marrow 
dendritic cells to block the aggregation of α-Syn, a pathological process implicated in PD 
progression. siRNA-loaded exosomes decorated with RVG (targeting ligand) effectively 
reduced the α-Syn aggregation in normal mice and transgenic mice expressing the human 
phosphorylation-mimic S129D α-Syn [139]. Dopamine-loaded exosomes derived from the 
blood of mice were used to deliver drugs across the BBB with lower systemic toxicity 
compared to i.v. administration of naked dopamine [140]. As an alternative approach, Haney 
et al. (2015) circumvented the BBB, using intranasal delivery to successfully administer the 
catalase-loaded macrophage-derived exosomes to the brain of mice with a model of PD, 
resulting in significant neuroprotective effects [119]. Conversely, a potential role of exosomes 
in diagnosing neurodegenerative conditions was highlighted by Gui et al. (2015) who 
developed a microRNA-profiling strategy for the early detection of PD. They used exosomes 
isolated from the CSF of PD and AD patients, reporting sixteen miRNAs upregulated and 11 
miRNAs under regulated in PD [141]. 
Liu et al. (2015) successfully deployed exosomes expressing RVG on the surface loaded 
with opioid receptor mu (MOR) siRNA into the brain for the treatment of morphine addiction 
[142]. Wu et al. (2018) also used RVG decorated exosomes for brain drug delivery. They 
encapsulated siRNA targeting human huntingtin exon 1 (HuHtt) transcript. HuHtt-siRNA 
loaded RVG-exosomes were then administered intravenously to normal mice and BACHD and 
N171-82Q transgenic (Huntington’s Disease-model) mice at 10 mg/kg every two days for 2 
Page 26 of 58AUTHOR SUBMITTED MANUSCRIPT - NANOX-100084.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 Ac
ce
pte
d M
an
u
cri
pt
27 
 
weeks. siRNA-loaded RVG exosomes significantly reduced HuHtt mRNA and protein levels 
up to 46% and 54%, respectively, in transgenic animals [143]. 
4.4. Liposomes for brain drug delivery 
Liposomes are self-assembled NPs made up of phospholipid bilayer membrane. 
Phospholipids are heterogeneous molecules containing phosphate residues, polar head groups, 
and non-polar alkyl chains [144] that self-assemble (according to the fluid mosaic model) into 
biological membranes. Liposomes for brain drug delivery have been studied extensively in the 
last two decades. 
Pulford et al. (2010) formulated liposomes (178 ± 20 nm) containing cationic lipid 
octadecenolyoxy[ethyl-2-heptadecenyl-3 hydroxyethyl] imidazolinium chloride to deliver 
siRNA into the brain of mice following i.v. injection. The cationic liposome-siRNA-peptide 
(RVG-9r) penetrates the BBB, with the peptide moiety binding to nAChRs [145]. Bender et al. 
(2016) used two liposomal systems for the delivery of prion protein siRNA to the brain of mice 
following i.v. injection. One of the liposome formulations was cationic liposomes containing 
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), which formed a complex with siRNA 
and RVG peptide. The other liposomal system contained DOTAP or 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine (DSPE) to encapsulate the siRNA. Both systems decreased the prion 
protein expression of neurons in the CNS [146]. Grinberg et al. (2005) reported novel cationic 
amphiphilic compounds synthesised from vernonia oil. The quaternary methyl ester derivative 
of methyl vernolate self-assembled into vesicles (in the presence of cholesterol 1:1) with the 
size of 50-200 nm in diameter [147]. Vesicles made from the quaternary vernonia oil derivative 
(triple-headed amphiphile) were found to be efficient in transfection of cDNA encoding for 
GFP into cultured COS-7 cells [147]. These vesicles were employed to deliver analgesic 
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peptides (kyotorphin or leu-enkephalin) to the brain of male ICR mice following i.v. injection 
[148]. 
Moreover, Conceicao et al. (2016) reported that the RVG-9r peptide decorated liposomes 
(also referred as stable nucleic acid lipid particles [SNALPs]) were able to cross the BBB and 
deliver siRNA, which can target mutant ataxin-3 in the brain of Machado-Joseph disease mouse 
models. These SNALPs offered high encapsulation of siRNA, optimum particle size and 
almost no toxicity. In vivo experiments showed the ability of SNALPs to accumulate in the 
brain and silence the mutant ataxin-3 upon i.v. injection as shown in Figure 4 [149]. 
 
Figure 4.  In vivo images showing the uptake of the RVG-9r decorated SNALPs in mice (C57 
BL/6 ataxin-3 [Q69]-transgenic) after i.v. injection reproduced from [149] after permission 
(NI: non-injected animal, RV-MAT-9r: non-targeted liposomes, RVG-9r: targeted-liposomes). 
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Table 2. A summary of formulations (NPs) targeting the BBB. 
Formulation/Polymer Drug Disease Method used for 
NP preparation 
Mechanism for 
BBB crossing 
Key Findings Ref 
g7-PLGA-NPs 
(NPs of less than 300 nm) 
 
FITC-albumin MPS I and MPS 
II 
Double emulsion technique RMT The C57BL/6 Idua 
knockout and C57BL/6 
Ids knockout mice were 
used. 
High MW molecule 
delivery across the BBB 
achieved 
[93] 
Functionalized solid lipid 
NPs with apolipoprotein E, 
(SLN-DSPE-ApoE) 
(Average size was less than 200 nm 
with zeta potential of –10-15 mV) 
 
Resveratrol  Neuroprotective High shear homogenization LDLR In vitro cytotoxicity 
evaluation via MTT and 
LDH using hCMEC/D3 
cell line showed that 
SLNs affected neither 
[150] 
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the metabolic activity of 
the cells nor the 
membrane integrity at 
concentrations less than 
1500 µg/mL. 
hCMEC/D3 monolayers 
in transwell devices 
showed SLN-DSPE-
ApoE, permeabilities 
1.5-fold higher than for 
non-functionalized 
SLNs 
Bovine Serum Albumin NPs 
with LMWP cell penetrating 
peptide (LMWP-albumin) 
PTX and 4-HPR Brain cancer Self-assembly Brain penetration 
mainly by EPR, but 
also through 
SPARC and gp60 
FACS showed in vitro 
cellular uptake of the 
NPs. 
[151] 
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[LMWP: 
CVSRRRRRRGGRRRR] 
(Particle size less than 200 nm,) 
albumin binding 
proteins 
overexpressed in 
glioma tissues 
bEnd.3 cell line showed 
BBB penetration of the 
NPs 
U87 cells showed 
cytotoxicity of NPs. The 
NPs were administered 
by i.v. injection to 
orthotopic glioma (Luc-
U87) mouse model 
(bearing intracranial 
tumor). The mice 
received the NPs 
(LMWP-modified 
bovine serum albumin 
(BSA) NPs containing 
PTX and 4-HPR) 
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showed the longest 
survival time 
PEG–PLA-penetratin 
(RQIKIWFQNRRMKWKK) 
(Particle size 100 nm, zeta potential 
-4.42 mV) 
Coumarin-6 CNS disorders Emulsion/solvent 
evaporation technique 
AMT/RMT MDCK-MDR cell model 
showed enhanced 
accumulation via both 
lipid raft-mediated 
endocytosis and direct 
translocation. In vivo 
administration showed 
significant brain uptake 
with less deposition in 
non-target tissues 
[152] 
Angiopep conjugated with 
poly(ethylene glycol)-co-
poly(ε-caprolactone): ANG-
PEG– poly(ε-caprolactone) 
Paclitaxel Glioblastoma 
multiforme 
Sonication LDLR U87 MG glioma cells 
indicated  the ANG-
PEG- poly(ε-
caprolactone) NPs 
[153] 
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(Particle size was less than 100 nm 
with zeta potential of 3.28 ± 0.75 
mV) 
uptake via LDLR 
(Angiopep-2 and 
Aprotinin significantly 
reduced the cellular 
uptake of the NPs). Real 
time fluorescence 
imaging showed 
accumulation of ANG-
NPs in the brain of 
intracranial U87 MG 
glioma tumor-bearing 
nude mice after i.v. 
injection. 
TAT-poly(ethylene glycol) 
(PEG)-b-cholesterol: TAT–
PEG-b-Chol 
Ciprofloxacin Encephalitis Self-assembly AMT Enhanced in vitro 
cellular (ACBRI 376) 
uptake. NPs crossed the 
[154] 
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(Particle size less than 200 nm) BBB and located around 
the cell nucleus of 
neurons (SD adult rats) 
following i.v. injection 
RVG-29-PEG-PLGA/DTX-
NPs 
(Particle size was around 110 nm) 
Docetaxel Gliomas Nanoprecipitation nAchR In vitro bEnd3 cells 
showed ermeability 
across the BBB. RVG-
29-PEG-PLGA/DTX-
NPs had a stronger 
inhibitory effect on C6 
cell proliferation than 
free DTX. In vivo 
experiments confirmed 
selective accumulation 
of NPs in intracranial 
[155] 
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glioma tissues following 
i.v. injection. 
PEG-Poly(ε-caprolactone)-
CH2R4H2C/Stearate- 
CH2R4H2C 
(CH2R4H2C: 
CHHRRRRHHC peptide) 
(Particle size was in the range of 50-
100 nm with zeta potential of 15-20 
mV) 
Dextran (as model 
drug) 
CNS disorders Self-assembly Olfactory nerve 
channels 
Hydrophobic carrier is 
more suitable for the 
delivery of drug in 
forebrain, while 
hydrophilic carrier is 
suitable for hindbrain 
(brainstem). 
[156] 
g7- PLGA-Np 
(Particle size was in the range of 
155±26 nm with zeta potential of -
15±5.6 mV) 
 
Loperamide CNS disorders Nanoprecipitation AMT Long term in vitro 
release over 192 hours 
and 20% in 2 hours. In 
vivo experiments 
showed excellent bio-
distribution in brain.  
[157, 
158] 
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mPEG−PLGA-RVG 
(Particle size was in the range of 
168.8 ± 1.9 nm with zeta potential 
of −27.40 ± 0.71 mV) 
Deferoxamine PD Double emulsion technique nAchR In vivo administration 
reduced the oxidative 
stress and iron contents 
in the substantia nigra 
and striatum of PD mice. 
[159] 
siRNA/TMC–PEG-RVG 
(Particle size was in the range of 
207 ± 2 nm with zeta potential of 9 
± 2.5 mV) 
siRNA AD - nAchR In vitro and in vivo 
experiment showed 
excellent penetration 
into brain with low 
toxicity and higher 
serum stability. 
[160] 
AuNCs-RDP 
(Particle size was in the range of 10 
± 2.85 nm with zeta potential of -
5.92 ± 3.16 mV) 
Carboxyfluorescein Neural cell 
imaging 
Green synthetic route RMT In vitro and in vivo 
results suggested the 
effective internalization 
in the brain cells. 
[161] 
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4.5. Dendrimers for brain drug delivery 
Dendrimers are chemically synthesised polymeric particles with defined shapes (due to 
monodispersity). Dendrimers have been investigated for brain drug delivery. It has been 
reported, apolipoprotein A-I (ApoA-I) and NL4-peptide dual modified dendrimer NPs were 
efficient carriers for siRNA delivery to PC12 cells and efficiently penetrate through a bEnd.3 
monolayer via LDLR [162]. KE et al. (2009) used PAMAM–PEG–Angiopep/DNA-NPs to 
deliver plasmid DNA across the BBB. The PAMAM was fifth generation with 128 surface 
primary amino groups. In vitro BBB model showed clathrin and caveolae-mediated 
endocytosis (also partly through marcopinocytosis) of the nanocarriers containing Angiopep 
peptide [TFFYGGSRGKRNNFKTEEYC]. PAMAM–PEG–Angiopep dendrimers were 
loaded with pEGFP plasmid; and the NPs were administered intravenously to mice. Gene 
expression was observed in all four regions of the mouse brain for the PAMAM–PEG–
Angiopep/DNA NPs, which was much higher than those for the PAMAM/DNA NPs [163]. In 
another study, low generation lysine dendrons (G0 and G1) conjugated with ApoE derived 
peptide (LRKLRKRLLR) were reported to cross the BBB efficiently with no cytotoxicity up 
to 400 µM [164]. It should be noted that PAMAM/siRNA complexes appear to show 
significant cell toxicity even at low concentrations such as 20 µg/mL [165]. As it would be 
expected, the cationic dendrimers show haemolytic activity. However, increasing the 
dendrimer generation decreases the haemolytic activity. For example, G2 dendrimers showed 
100% haemolysis at 1 mg/mL concentration after 24 h incubation with RBCs, while G5 
dendrimers showed no haemolysis (comparable to negative control) at the same concentration 
and incubation period [166]. Dynamic light scattering (DLS) studies showed that 
PAMAM/siRNA complexes had sizes in the range of 150-200 nm, while TEM results indicated 
a wider size distribution with majority in the range of 30-45 nm for G7 PAMAM/siRNA with 
N/P ration of 10 [167]. 
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4.6. Carbon Nanotubes  
Carbon nanotubes (CNT) are cylindrical molecules that consist of rolled-up sheets of 
single-layer carbon atoms. Distinctive properties of CNT such as good electronic properties, 
excellent penetration into cell membrane, high loading capacity, pH-dependent unloading, 
greater surface area and ease of modification make them one of the suitable drug delivery 
system for the brain [168, 169]. CNT have been extensively investigated as a drug carrier to 
the brain in past few years. Functionalized CNT can potentially be used as a carrier for drugs 
that have poor permeability across the BBB and also can be used for diagnostic and for the 
treatment of brain disorders [170]. 
CNT can be synthesized electric arc discharge and laser ablation using vaporisation of 
graphite target [171] or by chemical vapour deposition [172]. CNT can be grouped into single 
wall carbon nanotubes (SWCNT) or multi wall carbon nanotubes (MWCNT) depending on the 
number of layers that constitute a CNT. CNT size ranges from 0.4nm to 100nm depending on 
the layers. CNT can be functionalized covalently or non-covalently [173]. 
Ren et al. (2012) developed PEGylated oxidized multi-walled carbon nanotubes (O-
MWNTs) modified with angiopep-2 (O-MWNTs-PEG-ANG) to treat brain glioma. They 
reported the high uptake and accumulation of CNT in the desired area with excellent loading 
capacity. Angiopep-2 specifically binds to LDLR and promotes the internalization. 
Doxorubicin loaded CNT were found to have better anti-glioma effects than naked doxorubicin 
[174]. In another study, ANG functionalized radiolabelled CNT were employed to deliver drug 
across the BBB. In vitro experiments suggested higher penetration of ANG-CNT than 
chemically functionalized CNT. Enhanced localization of ANG-CNT was reported upon in 
vivo injection and 2% of the injected dose was accumulated in the brain within the first hour 
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post-injection [175, 176]. TAT (YGRKKRRQRRR) conjugated CNT were reported to have 
excellent BBB penetration and anticancer activity through increased ROS production [177]. 
4.7. Parameters affecting the BBB transport 
4.7.1. Size, morphology and surface zeta potential  
NPs in the range of 120-180 nm after crossing the BBB may be entrapped in the BL [178]. 
However, NPs with the size in the range of 16-24 nm are able to diffuse in the brain parenchyma 
[178]. These observations indicate that NPs should be less than 120 nm such as exosomes in 
order to diffuse in the brain parenchyma, otherwise they will remain trapped in the BL 
following crossing the BBB. 
The morphology of NPs affects their bio-distribution and cellular uptake. NPs could be 
spherical, cubic, tubular or rod-like in shape [179, 180]. A majority of the particles reported 
for brain delivery are roughly spherical in shape. Zeta potential or surface charge of NPs is 
another factor that controls the diffusion across the BBB. It has been reported that a high 
(positive) zeta potential causes toxicity to the BBB [181, 182]. Rassu et al. (2017) reported that 
a positive surface charge on NPs ensures their mucoadhesion [183]. On the other hand, NP 
formulations have been reported for brain delivery with zeta potentials between -1 and -45 mV 
[184, 185, 186]. Different shapes of NPs are shown in Figure 5. 
 
Page 39 of 58 AUTHOR SUBMITTED MANUSCRIPT - NANOX-100084.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 Ac
ce
pte
d M
an
scr
ipt
40 
 
 
Figure 5. Different morphologies and shapes of NPs used for brain drug delivery. 
4.7.2. Critical micelle concentration (CMC) 
CMC is the minimum concentration of a compound at which it forms micelles. CMC 
plays a major role in the stability of micelles/NPs due to excessive dilution in the blood, upon 
i.v. injection. If the concentration in systemic circulation drops below the CMC, then it releases 
the payload in the blood stream before getting to its target. 
CMC can be determined by using set concentrations of a pyrene probe with serial dilution 
of copolymer solution [187, 188]. Ruan et al. (2018) used RAP12 peptide (a part of the receptor 
associated protein that binds to LRP1) and decorated PEG-poly(lactic acid) (PLA) micelles to 
deliver  drug (paclitaxel) across the BBB [189]. Liu et al. (2009) reported CG3R6TAT 
(CGGGRRRRRRYGRKKRRQRRR), a self-assembled cationic antimicrobial peptide able to 
cross the BBB. They measured the CMC by using the pyrene as a probe and found to be 31.6 
mg/L (10.1 µM) in deionized water [187]. Micelles and PMNPs both can target the brain and 
cross the BBB. Efficacy and efficiency of crossing the BBB are dependent on targeting via the 
surface of the nanocarriers. 
4.7.3. Protein corona 
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NPs, upon contact with biological fluids, are surrounded by a protein layer that is called 
protein corona [190, 191, 192, 193]. The first layer of protein corona is bound tightly on the 
surface (primary contact with NPs), which is referred as ‘‘hard’’ corona. Usually, another layer 
is loosely bound on the first layer, which is referred as ‘‘soft’’ corona; and that consists of 
serum proteins, mainly comprising albumin and its derivatives [194, 195, 196]. This surface 
adsorption of protein can alter the physiological response [195]. The adsorption of proteins on 
NPs mostly has undesirable effects such as prompt clearance from blood stream, compromised 
targeting capacity [197] and toxicity [198, 199]. Proteins bound to a NP surface may rearrange 
their structure and shape according to NP surface and environment, this is known as 
‘‘conformational change’’. Conformational change accompanied with the modification of 
secondary or tertiary protein structure. Proteins are supposed to interact with other 
biomolecules to initiate biological responses, hence a small modification in protein structure 
has huge impact on their pharmacological activities [200]. 
Several factors dictate the nature of adsorbed proteins. Particle size plays an important 
role in protein adsorption. As NPs are bigger than proteins, NPs make proteins to adapt the 
NPs’ surface. Smaller NPs has less interaction with proteins [201]. Surface charge of the NPs 
affects the secondary structure of proteins. Huhn et al. (2014) reported that gold NPs with 
different surface charge (positive [+9.7 ± 8.9 mV] or negative [-39.8 ± 10.0 mV]), but similar 
sizes adsorbed comparable amounts of HSA. Whereas, positively charged NPs showed higher 
cellular uptake than negatively charged NPs. This change in the activity can be due to 
conformation changes in protein structure due to surface charge [202]. Fleischer and Payne 
(2014) observed that similar NPs with identical protein corona compositions bind to different 
cellular receptors, suggesting that a difference in the structure of the adsorbed protein may be 
responsible for the differences in cellular binding of the protein–NP complexes. These authors 
also found that cationic polystyrene NPs showed improved cellular binding to monkey kidney 
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epithelial cells compared to negatively charged NPs in the presence of fetal bovine serum 
(FBS). It should be noted that in both cases, the NPs formed protein–NP complexes 
immediately following exposure to FBS [199]. 
Media composition affects the protein corona. Silica NPs in the presence of serum 
proteins showed less uptake compared to serum free media [203]. Gold NPs incubated with 
Dulbecco’s Modified Eagle’s Medium (DMEM) media for 48 h showed higher protein 
adsorption than Roswell Park Memorial Institute media (RPMI), but same amount after 1 hr 
incubation [204]. Protein concentration in media affects the protein corona. Silica NPs 
incubated with 3%, 20% and 80 % plasma exhibited different protein patterns. Changes in 
primary protein band was observed with increasing plasma concentration. Lower amounts of 
proteins were measured on silica NPs compared to sulfonated polystyrene (PSOSO3) NPs with 
increased plasma concentrations [205]. Exposure time affects the protein corona. Protein 
corona forms immediately as soon as the NPs come into contact with human plasma. Tenzer et 
al. (2013) reported complex protein corona (formed of 300 proteins) just after 30 s [206]. In 
addition, temperature plays an important role in protein corona formation. Cu-NPs showed 
higher protein adsorption when incubated by increasing temperature from 15°C, 27°C, and 
37°C to 42°C [207]. 
A decline (from 76% to 26%) in the cellular uptake of cRGD decorated NPs was reported 
by Su et al. (2018) in protein bound NPs compared to non-protein bound NPs. They found that 
even the targeting ability was not affected but cellular uptake was compromised [208]. Tf 
decorated NPs were reported to lose their targeting ability in the biological medium. Proteins 
in the medium are reported to shield the NPs and hence results in disappearance of targeting 
ability. However NPs can enter the cells but the targeting capacity is lost [209]. Aptamer 
functionalized AuNPs lost the targeting ability due to protein corona blocking after serum 
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exposure. Immune related proteins were found on the surface of aptamer that can induce 
immune reaction and clearance eventually [210]. 
4.7.4. Stability of NPs 
The stability of NPs can be categorised into two, shelf stability and serum stability. NPs 
should be stable enough to retain their therapeutic effects for a specific time when stored or 
administered to the body. Oller‐Salvia et al. (2016) tested the serum stability of peptide NPs in 
human serum. They found that switching from linear to monocyclic analogue didn’t affect the 
permeability but showed 30-fold enhanced stability than linear peptide analogue [32]. In 
addition, upon switching disulphide to a lactam bridge in Miniap-4 shuttle peptide, they found 
50% higher permeability with better resistance to proteases [32]. El-Marakby et al. (2017) 
assessed the serum stability of chitosan NPs in rat serum. They reported a sharp reduction in 
particle size (up to 62% of original size) prepared from the native chitosan, whereas modified 
chitosan showed slight increase in the size from 87.39 ± 1.56 nm to 122.33 ± 1.95 nm after 2 
h incubation with the serum. After 24 h incubation no significant changes were noticed [211]. 
Oliveira et al. (2017), tested uncoated and poly allylamine hydrochloride (PAH)-coated PLGA-
NPs in biological environments: BSA solution, mouse and human plasma. Both formulations 
were reported stable in BSA and mouse plasma on incubation, but surprisingly not stable in 
human plasma (formed aggregates greater than 1 µm). They also studied protein corona in all 
solutions. In mouse plasma uncoated NPs showed protein concentration of 4.1 ± 2.6 μg/mL, 
which was much greater than incubating these NPs in BSA solution. Surprisingly, in human 
plasma it was 2.5-fold higher (10.4 ± 3.0 μg/mL) than mouse plasma. Similarly PAH-coated 
PLGA-NPs showed higher protein adsorption after incubation with human plasma than BSA 
solution and mouse plasma [212]. 
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Uncoated chitosan NPs were to increase in size by storage at 25C for 3 months in 10% 
glucose solution [213]. This alteration in size results in modified physicochemical, 
pharmacodynamic and pharmacokinetic properties of the PMNPs. Lyophilisation with 
cryoprotectants is reported to enhance the stability and to stop contents leaking from the NPs 
[214, 215, 216]. Cryoprotectants such as glucose, sucrose, mannitol and trehalose are most 
commonly used because of their low toxicity [214, 217]. 
5. Conclusion 
Peptide based drug delivery systems have been studied extensively in the last two decades 
to overcome the BBB. Peptide based formulations come with its advantages (less toxicity, low 
alteration in the BBB integrity and specific targeting) and disadvantages (serum stability). 
Shuttle peptides, exosomes, liposomes, NPs and dendrimers decorated with peptides have 
shown much improved permeability across the BBB. Targeting and crossing the BBB is an 
ever expanding and challenging yet promising field. To design and develop a CNS drug that 
can target the BBB requires a detailed understanding of both the BBB at a molecular level and 
drug properties (pharmacokinetics and pharmacodynamics). Despite many advances in drug 
delivery systems, there is still an essential need for research aimed at attaining improved 
delivery systems with fewer limitations. Peptide based delivery systems along with pro and 
cons need further optimization and high specificity in brain targeting. 
 
 
6. Future Direction 
Despite extensive research in the use of peptides in nanoparticles for drug delivery to the 
brain, yet there is no clinical trial of them. Then, the next steps would be developing scalable 
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and reproducible brain targeting nanoparticle delivery system using peptides as targeting 
ligands. Peptide based NPs provide the opportunity of formulating enzyme responsive or 
biodegradable delivery systems, which may offer less toxicity and immunogenicity, and 
improved efficacy. Peptide based nanoparticles should be able to deliver/encapsulate suitable 
amounts of drug to the brain; and these should protect the drug from enzymes in the blood.  
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